The World Health Organization (WHO) has made a significant advancement in malaria treatment by prequalifying the first formulation specifically designed for infants weighing between 2 and 5 kg. Previously, infants received scaled-down doses of medications meant for older children, which posed risks of errors and side effects. The new treatment, a formulation of artemether-lumefantrine (commonly known as Coartem), allows governments and health agencies to procure a quality-assured drug tailored for young patients. WHO Director-General Tedros Adhanom Ghebreyesus emphasized that this development, alongside vaccines and diagnostics, strengthens the global response to malaria. Additionally, the WHO has prequalified three new rapid diagnostic tests that address detection challenges posed by mutations in malaria-causing parasites. The World Malaria Report 2025 estimated 282 million malaria cases and 610,000 deaths in 2024, with children under five being the most affected, particularly in Africa. Despite progress made since 2000, the WHO noted that global efforts have slowed due to drug resistance and funding declines.